These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 17502100)

  • 1. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.
    Piper DE; Jackson S; Liu Q; Romanow WG; Shetterly S; Thibault ST; Shan B; Walker NP
    Structure; 2007 May; 15(5):545-52. PubMed ID: 17502100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
    Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of PCSK9 function.
    Lambert G; Charlton F; Rye KA; Piper DE
    Atherosclerosis; 2009 Mar; 203(1):1-7. PubMed ID: 18649882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA
    Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for LDL receptor recognition by PCSK9.
    Kwon HJ; Lagace TA; McNutt MC; Horton JD; Deisenhofer J
    Proc Natl Acad Sci U S A; 2008 Feb; 105(6):1820-5. PubMed ID: 18250299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
    Costet P; Krempf M; Cariou B
    Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo.
    Ni YG; Di Marco S; Condra JH; Peterson LB; Wang W; Wang F; Pandit S; Hammond HA; Rosa R; Cummings RT; Wood DD; Liu X; Bottomley MJ; Shen X; Cubbon RM; Wang SP; Johns DG; Volpari C; Hamuro L; Chin J; Huang L; Zhao JZ; Vitelli S; Haytko P; Wisniewski D; Mitnaul LJ; Sparrow CP; Hubbard B; Carfí A; Sitlani A
    J Lipid Res; 2011 Jan; 52(1):78-86. PubMed ID: 20959675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
    Gauthier MS; Pérusse JR; Awan Z; Bouchard A; Tessier S; Champagne J; Krastins B; Byram G; Chabot K; Garneau P; Rabasa-Lhoret R; Faubert D; Lopez MF; Seidah NG; Coulombe B
    Methods; 2015 Jun; 81():66-73. PubMed ID: 25770357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R).
    Palmer-Smith H; Basak A
    Curr Med Chem; 2010; 17(20):2168-82. PubMed ID: 20423303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap.
    Pearlstein RA; Hu QY; Zhou J; Yowe D; Levell J; Dale B; Kaushik VK; Daniels D; Hanrahan S; Sherman W; Abel R
    Proteins; 2010 Sep; 78(12):2571-86. PubMed ID: 20589640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor.
    Holla ØL; Laerdahl JK; Strøm TB; Tveten K; Cameron J; Berge KE; Leren TP
    Biochem Biophys Res Commun; 2011 Mar; 406(2):234-8. PubMed ID: 21324305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion.
    Cameron J; Holla ØL; Berge KE; Kulseth MA; Ranheim T; Leren TP; Laerdahl JK
    FEBS J; 2008 Aug; 275(16):4121-33. PubMed ID: 18631360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.
    Qian YW; Schmidt RJ; Zhang Y; Chu S; Lin A; Wang H; Wang X; Beyer TP; Bensch WR; Li W; Ehsani ME; Lu D; Konrad RJ; Eacho PI; Moller DE; Karathanasis SK; Cao G
    J Lipid Res; 2007 Jul; 48(7):1488-98. PubMed ID: 17449864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Schulz R; Schlüter KD; Laufs U
    Basic Res Cardiol; 2015 Mar; 110(2):4. PubMed ID: 25600226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.
    Mbikay M; Mayne J; Chrétien M
    J Diabetes; 2013 Dec; 5(4):391-405. PubMed ID: 23714205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.